{
    "id": "18928e94-a9ff-44a6-a65e-c6f8c21c815c",
    "indications": {
        "text": "fluticasone furoate/vilanterol ellipta combination fluticasone furoate , corticosteroid , vilanterol , long\u2011acting beta 2 -adrenergic agonist ( laba ) , indicated : \u2022 maintenance treatment patients chronic obstructive pulmonary disease ( chronic obstructive pulmonary disease ) . ( 1.1 ) \u2022 maintenance treatment asthma patients aged 5 years older . ( 1.2 ) limitations : indicated relief acute bronchospasm . ( 1.3 , 5.2 )",
        "doid_entities": [
            {
                "text": "chronic obstructive pulmonary disease (DOID:3083)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3083"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "asthma (DOID:2841)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2841"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 oral inhalation . ( 2.3 ) \u2022 maintenance treatment chronic obstructive pulmonary disease : 1 actuation fluticasone furoate/vilanterol ellipta 100/25 mcg daily administered oral inhalation . ( 2.1 ) \u2022 maintenance treatment asthma adult patients aged 18 years older : 1 actuation fluticasone furoate/vilanterol ellipta 100/25 mcg fluticasone furoate/vilanterol ellipta 200/25 mcg daily administered oral inhalation . ( 2.2 ) \u2022 maintenance treatment asthma pediatric patients aged 12 17 years : 1 actuation fluticasone furoate/vilanterol ellipta 100/25 mcg daily administered oral inhalation . ( 2.2 ) \u2022 maintenance treatment asthma pediatric patients aged 5 11 years : 1 actuation fluticasone furoate/vilanterol ellipta 50/25 mcg daily administered oral inhalation . ( 2.2 )",
        "doid_entities": [
            {
                "text": "chronic obstructive pulmonary disease (DOID:3083)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3083"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "asthma (DOID:2841)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2841"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "fluticasone furoate/vilanterol ellipta supplied disposable light grey pale blue plastic inhaler containing 2 foil strips , 30 blisters . one strip contains fluticasone furoate ( 100 200 mcg per blister ) , strip contains vilanterol ( 25 mcg per blister ) . blister strip used create 1 dose . inhaler packaged within moisture\u2011protective foil tray desiccant peelable lid following packs : ndc 66993-135-97 100/25 mcg 30 inhalations ( 60 blisters ) ndc 66993-136-97 200/25 mcg 30 inhalations ( 60 blisters ) store room temperature 68\u00b0f 77\u00b0f ( 20\u00b0c 25\u00b0c ) ; excursions permitted 59\u00b0f 86\u00b0f ( 15\u00b0c 30\u00b0c ) [ usp controlled room temperature ] . store dry place away direct heat sunlight . keep reach children . fluticasone furoate/vilanterol ellipta stored inside unopened moisture\u2011protective foil tray removed tray immediately initial . discard fluticasone furoate/vilanterol ellipta 6 weeks opening foil tray counter reads \u201c 0 \u201d ( blisters used ) , whichever comes first . inhaler reusable . attempt take inhaler apart .",
    "adverseReactions": "fluticasone furoate/vilanterol ellipta contraindicated following conditions : \u2022primary treatment status asthmaticus acute episodes chronic obstructive pulmonary disease asthma intensive measures required [ ( 5.2 ) ] . \u2022severe hypersensitivity milk proteins demonstrated hypersensitivity fluticasone furoate , vilanterol , excipients [ ( 5.11 ) , description ( 11 ) ] .",
    "ingredients": [
        {
            "name": "FLUTICASONE FUROATE",
            "code": "JS86977WNV",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_74899"
        },
        {
            "name": "VILANTEROL TRIFENATATE",
            "code": "40AHO2C6DG",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_75037"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        }
    ],
    "organization": "Prasco Laboratories",
    "name": "Fluticasone Furoate and Vilanterol",
    "effectiveTime": "20241121",
    "indications_original": "Fluticasone Furoate/Vilanterol ELLIPTA is a combination of fluticasone furoate, a corticosteroid, and vilanterol, a long\u2011acting beta 2 -adrenergic agonist (LABA), indicated for: \u2022 the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1.1 ) \u2022 the maintenance treatment of asthma in patients aged 5 years and older. ( 1.2 ) Limitations of Use: Not indicated for relief of acute bronchospasm. ( 1.3 , 5.2 )",
    "contraindications_original": "\u2022 For oral inhalation only. ( 2.3 ) \u2022 Maintenance treatment of COPD: 1 actuation of Fluticasone Furoate/Vilanterol ELLIPTA 100/25 mcg once daily administered by oral inhalation. ( 2.1 ) \u2022 Maintenance treatment of asthma in adult patients aged 18 years and older: 1 actuation of Fluticasone Furoate/Vilanterol ELLIPTA 100/25 mcg or Fluticasone Furoate/Vilanterol ELLIPTA 200/25 mcg once daily administered by oral inhalation. ( 2.2 ) \u2022 Maintenance treatment of asthma in pediatric patients aged 12 to 17 years: 1 actuation of Fluticasone Furoate/Vilanterol ELLIPTA 100/25 mcg once daily administered by oral inhalation. ( 2.2 ) \u2022 Maintenance treatment of asthma in pediatric patients aged 5 to 11 years: 1 actuation of fluticasone furoate/vilanterol ELLIPTA 50/25 mcg once daily administered by oral inhalation. ( 2.2 )",
    "warningsAndPrecautions_original": "Fluticasone Furoate/Vilanterol ELLIPTA is supplied as a disposable light grey and pale blue plastic inhaler containing 2\u00a0foil strips, each with 30 blisters. \n                  One strip contains fluticasone furoate (100 or 200\u00a0mcg per blister), and the other strip contains vilanterol (25\u00a0mcg per blister). \n                  A blister from each strip is used to create 1 dose. The inhaler is packaged within a moisture\u2011protective foil tray with a desiccant and a peelable lid in the following packs:\n                  NDC 66993-135-97\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0100/25\u00a0mcg\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a030 inhalations (60 blisters)\n                  NDC 66993-136-97\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0200/25\u00a0mcg\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a030 inhalations (60 blisters)\n                  Store at room temperature between 68\u00b0F and 77\u00b0F (20\u00b0C and 25\u00b0C); excursions permitted from 59\u00b0F to 86\u00b0F (15\u00b0C to 30\u00b0C) [See USP Controlled Room Temperature]. Store in a dry place away from direct heat or sunlight. Keep out of reach of children.\n                  Fluticasone Furoate/Vilanterol ELLIPTA should be stored inside the unopened moisture\u2011protective foil tray and only removed from the tray immediately before initial use. Discard Fluticasone Furoate/Vilanterol ELLIPTA 6 weeks after opening the foil tray or when the counter reads \u201c0\u201d (after all blisters have been used), whichever comes first. The inhaler is not reusable. Do not attempt to take the inhaler apart.",
    "adverseReactions_original": "Fluticasone Furoate/Vilanterol ELLIPTA is contraindicated in the following conditions:\n                  \n                     \n                        \u2022Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required [see Warnings and Precautions (5.2)].\n                     \n                        \u2022Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate, vilanterol, or any of the excipients [see Warnings and Precautions (5.11), Description (11)].",
    "drug": [
        {
            "name": "Fluticasone Furoate and Vilanterol",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5134"
        }
    ]
}